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INTRODUCTION
The CC chemokine receptor CCR3 plays a major role 
in the development of allergic diseases by mediating 
the recruitment of allergic cells to inflamed sites (1). 
Eosinophils are primarily found in the inflammatory 
infiltrate, but Th2 cells also have critical roles in the 
allergic pathology (2). These cells express CCR3 on 
their cell surfaces (3). CCR3 appears to be regulated in 
a temporal manner during phenotypic differentiation of 
eosinophils and is expressed along with IL-5Rα at a basal 
level in eosinophil progenitors (4). After commitment of 
eosinophils, CCR3 expression gradually increases during 
differentiation and reaches its highest level at the terminal 
stage both in vivo (5) and in vitro (6). 
  CCR3 expression is mainly regulated at the transcription 
level. A region spanning exon 1 and proximal intron 1 of 
this gene have been shown to retain the critical sequence 
for transcriptional control (7-9). This sequence harbors 
multiple GATA sites for the zinc finger transcription factor 
GATA-1. We have previously mapped the functional 
GATA site within exon 1 of this gene, to which GATA-1 
binds with high affinity. Introduction of GATA-1 siRNA 
or dominant negative GATA-1 resulted in a significant 
reduction in CCR3 reporter activity (6). Although GATA-
1 acts as a key regulator of CCR3 gene transcription, it 
alone is unlikely to be sufficient for full transactivation of 
the reporter, since a point mutant lacking the functional 
GATA site exhibits 50~60% reduced transcription. Close 
examination reveals that, in addition to GATA sites, the 
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CCR3 is a chemokine receptor that mediates the accumulation of allergic inflammatory cells, including eosinophils 
and Th2 cells, at inflamed sites. The regulatory sequence of the CCR3 gene, contains two Runt-related transcription 
factor (RUNX) 1 sites and two PU.1 sites, in addition to a functional GATA site for transactivation of the CCR3 gene. 
In the present study, we examined the effects of the cis-acting elements of RUNX1 and PU.1 on transcription of the 
gene in EoL-1 eosinophilic cells and Jurkat T cells, both of which expressed functional surface CCR3 and these two 
transcription factors. Introduction of RUNX1 siRNA or PU.1 siRNA resulted in a modest decrease in CCR3 reporter 
activity in both cell types, compared with transfection of GATA-1 siRNA. Cotransfection of the two siRNAs led to 
inhibition in an additive manner. EMSA analysis showed that RUNX1, in particular, bound to its binding motifs. 
Mutagenesis analysis revealed that all point mutants lacking RUNX1- and PU.1-binding sites exhibited reduced 
reporter activities. These results suggest that RUNX1 and PU.1 participate in transcriptional regulation of the CCR3 
gene.
[Immune Network 2016;16(3):176-182]
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regulatory sequence of the CCR3 gene contains two 
cis-acting elements of the transcription factors Runt-
related transcription factor 1 (RUNX1) and PU.1. PU.1 is 
selectively expressed in B lymphocytes, granulocytes, and 
monocytes and is required for eosinophil development, 
regulating an eosinophil-specific gene in corporation 
with GATA-1 and CCAAT/enhancer binding protein 
alpha (10-14). It contains various distinct functional do-
mains, namely an Ets domain that recognizes the DNA 
sequence harboring the core GGAA motif (15). RUNX1 
is required for generation of hematopoietic lineages 
including myeloid lines (16,17). Genetically modified 
mice that do not express RUNX1 demonstrate a dramatic 
decrease in basophils but normal numbers of neutrophils 
and eosinophils, suggesting that RUNX1 plays a role 
in differentiation of basophils (18). RUNX1 binds to 
DNA in a sequence-specific manner, recognizing a TG-
TGGT consensus binding site (19). Given the intimate 
relationship of RUNX1 and PU.1 to hematopoietic com-
ponents and the presence of their cis-acting factors in the 
key regulatory region of the CCR3 gene, we investigated 
their involvement in CCR3 transcription. 
maTeRIals aND meTHODs
Cell culture
Jurkat cells were purchased from the Korean Cell Line 
Bank (Seoul, Korea). EoL-1 cells were kindly provided 
by Yun-Jae Jung (Gacheon University, Incheon, Korea). 
Jurkat and EoL-1 cells were maintained in RPMI medium 
(Welgene, Seoul, Korea) supplemented with 10% FBS, 
penicillin (100 U/ml), and streptomycin (100 μg/ml). 
CCR3 mRNa expression
Total mRNAs were extracted from cell lines using 
TRI reagent (Molecular Research Center, Cincinnati, 
OH, USA). First-strand cDNA was synthesized 
from 4 μg total RNA using SuperScript II Reverse 
Transcriptase (Invitrogen Life Technologies) in a 20 μl 
reaction containing random primers, deoxynucleotide 
triphosphates (0.5 mM), MgCl2 (2.5 mM), and DTT (5 
mM). Reverse transcription was performed at 42oC for 
1 h, followed by heat inactivation at 70oC for 15 min. 
The synthesized cDNA was amplified for 30 cycles with 
Ex DNA polymerase (TAKARA, Shiga, Japan). The 
following primers were used in the amplification: CCR3 
forward 5ʹ-ATGCTGGTGACAGAGGTGAT-3ʹ and 
reverse 5ʹ-AGGTGAGTGTGGAAGGCTTA-3ʹ; GAPDH 
forward 5ʹ-CGTCTTCACCACCATGGAGA-3ʹ and 
reverse 5ʹ-CGGCCATCACGCCACAGTTT-3.ʹ 
western blot analysis 
Cells were lysed in RIPA buffer (50 mM Tris-Cl [pH 
7.4], 0.1% NaN3, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 
and protease inhibitor mixture) supplemented with 0.4 
M NaCl. Lysates were centrifuged, and the resulting su-
pernatants were subjected to Western blot analysis. Thirty 
micrograms of the cell lysates were resolved with SDS-
PAGE and then transferred to polyvinylidene difluoride 
membranes. After the membranes were blocked with 5% 
nonfat dry milk, they were probed with anti-RUNX1 (N-
20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-PU.1 (T-21, Santa Cruz Biotechnology), and anti-
GAPDH Ab (Santa Cruz Biotechnology). The membranes 
were incubated with an anti-goat HRP-conjugated Ab 
(Santa Cruz Biotechnology) for RUNX1 and an anti-
rabbit HRP-conjugated Ab (Cell Signaling Technology, 
Beverly, MA, USA) for PU.1. Immunostained proteins 
were visualized using an ECL detection system 
(Amersham Biosciences, Buckinghamshire, UK).
flow cytometry 
Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich, 
St. Louis, MO, USA) for 15 min at 4oC, washed with 2% 
BSA in PBS, and then stained with PE-conjugated anti-
human CCR3 Ab (R&D Systems, Minneapolis, MN, 
USA) or isotype matched Ab (BD Pharmingen, San 
Diego, CA, USA). Stained cells were analyzed using a 
flow cytometer, and data analysis was performed using 
CellQuest Software (Becton Dickinson, San Jose, CA, 
USA). 
Chemotaxis
Chemotaxis assays were performed in 48-well Boyden 
chambers (Neuro Probe, Gaithersburg, MD, USA). 
EoL-1 and Jurkat cells were washed and resuspended 
in chemotaxis medium containing 1% BSA and 2 mM 
HEPES. Assays were performed in triplicates using 2× 
105 cells/well with a 5-μm-pore size PVPF membrane 
(Osmonics, Minnetonka, MN, USA). A 27 μl aliquot 
of indicated concentrations of eotaxin was added to the 
lower chamber. A filter was overlaid and then 50 μl of the 
cell suspension was added to the upper chambers. The 
chamber was incubated at 37oC in 5% CO2  for 3 h. Then, 
cells which migrated to the lower chamber were counted. 
Chemotaxis was expressed as a chemotaxis index.
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RNa interference
Small interfering RNA (siRNA)-dependent knockdown 
experiments were conducted using ON-TARGETplus 
SMARTpool siRNA for RUNX1, PU.1, GATA-1, and 
non-targeting (scrambled) control pools (Dharmacon, 
Chicago, IL, USA). Briefly, EoL-1 and Jurkat cells 
were cotransfected with siRNA and the CCR3 reporter 
using Amaxa 4D-nucleofector (Lonza, Koln, Germany) 
or Lipofectamine 2000 Reagent (Invitrogen Life 
Technologies) and examined for luciferase activities. 
Reporter gene plasmids, mutagenesis, and luciferase assay.
A pGL3-based luciferase reporter construct (Promega, 
Madison, WI, USA) that harbored exon 1 (249 bp) 
and the proximal intron 1 (157 bp) of the CCR3 
gene was previously described (6). RUNX1 and 
PU.1 sites were mutated using conventional overlap 
extension PCR with the primers listed in Table I. 
The RUNX1 site 5ʹ-AGTGGT-3ʹ was replaced with 
5ʹ-CTGTTG-3.ʹ The PU.1 sites, which occurred in 
tandem repeat as 5ʹ-GAGGAGAGGA-3,ʹ were mutated 
to 5ʹ-TCGGCTCGGC-3ʹ and treated as a single site. 
Amplification was performed using Pyrobest TaqTM 
(TAKARA) in a 50 μl reaction. The resulting PCR 
products were cloned into the pGL3 vector, and their 
sequences were confirmed through DNA sequencing 
analysis. Cell lines were transfected with the reporter 
plasmids. Luciferase activity was measured using the 
Dual-Luciferase Reporter System (Promega), and 
transfection efficiency was normalized to Renilla 
luciferase activity from cotransfection with pRL-TK 
vector (Promega).
Nuclear extract and emsa
After lysis with RIPA buffer containing 0.15 M NaCl, 
the lysate was centrifuged. The pellet was resuspended in 
RIPA buffer containing 0.4 M NaCl. The supernatant was 
then used for EMSA analysis. Four micrograms of the 
nuclear extracts were incubated with 32P-labeled probe for 
20 min in binding buffer (50 mM Tris-Cl [pH 7.5], 20% 
glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 
250 mM NaCl, and 0.25 mg/ml poly[dI-dC]•poly[dI-
dC]). For supershift analysis, extracts were incubated 
with anti-RUNX1 (N-20, Santa Cruz Biotechnology), 
anti-PU.1 (T-21, Santa Cruz Biotechnology), or control 
antibodies (Sigma-Aldrich), followed by a radiolabeled 
probe. Reaction mixtures were analyzed through 
separation on 6% polyacrylamide gels. RUNX1 and 
PU.1 site probes are as follows: RUNX1 upstream 
site, 5ʹ-TTTCAGGAGTGGTGACGCCT-3ʹ; RUNX1 
downstream site, 5ʹ-AGCAGGTACCACTGGTCTTC; 
PU.1 site, 5ʹ- GGAGGGAGGAGAGGAAGGTA-3.ʹ
statistical analysis
All statistical analyses were performed using the Mi-
crosoft Excel data analysis program or SPSS 12.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). An independent 
t test was used to compare relative reporter activities 
between the two groups. Comparisons of the activities 
in three or more independent groups were performed 
using one-way ANOVA, followed by post-hoc analysis. 
Differences with a p-value less than 0.05 were considered 
statistically significant. The results are expressed as mean 
±SEM. 
ResUlTs aND DIsCUssION
We chose the two cell lines EoL-1 and Jurkat, which 
represent eosinophils and T cells, respectively. RT-
PCR and FACS analyses showed that the two cell types 
constitutively expressed not only CCR3 mRNA but also 
surface CCR3 protein at their surfaces (Fig. 1A). The 
surface CCR3 protein was functional in both cell types, 
as evidenced by typical chemotactic responses to eotaxin, 
a CCR3 ligand (Fig. 1A). These two cells also expressed 
both RUNX1 and PU.1 proteins, as analyzed using RT-
PCR (data not shown) and immunoblots (Fig. 1B). 
  We previously constructed a CCR3 reporter plasmid 
that spans exon 1 and the proximal intron 1 sequence 
(6), which includes two RUNX1 and two PU.1 sites. 
As EoL-1 and Jurkat cells expressed both RUNX1 and 
Table I. Primers used in overlap extension PCR to generate point mutants
Distal RUNX1 site Forward GGATCTAGGAGGTCGGCTCGGCAGGTACACAGCA
Reverse TGCTGTGTACCTGCCGAGCCGACCTCCTAGATCC
Proximal RUNX1 site Forward TCTGTTTCAGGCTGTTGGACGCCTAAGCT
Reverse AGCTTAGGCGTCCAACAGCCTGAAACAGA
PU.1 site Forward AAATTAGCAGGTCAACAGGGTCTTCTTGTG
Reverse CACAAGAAGACCCTGTTGACCTGCTAATTT
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PU.1 transcription factors (Fig. 1B), we examined the 
involvement of RUNX1 and PU.1 in reporter activation. 
To this end, RUNX1 and PU.1 siRNAs were transfected 
into EoL-1 and Jurkat cells. GATA siRNA and scramble 
siRNA were used as positive and negative controls, 
respectively. GATA-1 siRNA reduced the reporter activity 
by 60% in both cell types, as observed in our previous 
report, while RUNX1 and PU.1 siRNAs reduced reporter 
activity by 22% and 28%, respectively (Fig. 2). An 
additive effect (40%) was observed upon cotransfection 
of RUNX1 and PU.1 siRNAs. This result indicates that 
RUNX1 and PU.1 participate in activation of CCR3 
transcription, although they have a weaker effect than 
GATA-1. 
  The nucleotide sequence of the regulatory region of the 
CCR3 gene is shown in Fig. 3A. This region contains 
two RUNX1 sites in exon 1 and two tandem PU.1 sites 
in the proximal sequence of intron 1, in addition to the 
GATA site in exon 1 that has been demonstrated to be 
important for reporter activity (6). A point mutation in the 
functional GATA site (Construct 2 in Fig. 3B) resulted in 
a significant reduction in CCR3 reporter activity in EoL-
1 and Jurkat cells, which is consistent with a previous 
report (20). Mutation in either of the two RUNX1 sites 
(constructs 3 and 4) resulted in a decrease in CCR3 
reporter activity, with a smaller effect at the upstream 
RUNX1 site than the downstream RNUX1 site. Double 
Figure 1. Expression of CCR3, RUNX1, and PU.1 in Jurkat and EoL-1 
cells. (A) Expression of CCR3 mRNA and protein was analyzed using 
RT-PCR and FACS, respectively, and chemotactic responses to eotaxin 
(1~200 ng/ml) was analyzed. The results shown are representative 
of three to five independent experiments. Statistical significance was 
obtained using SPSS, compared with medium. *p<0.05 and **p<0.01. 
(B) Expression of RUNX1 and PU.1 proteins was analyzed using 
Western blotting. GAPDH mRNA and protein were used as loading 
controls. The results shown are representative of three independent 
experiments.
Figure 2. Effects of RUNX1 and PU.1 siRNAs on CCR3 reporter 
activity. Cells were co-transfected with 50 nM siRNAs for RUNX1, 
PU.1, GATA-1 or scramble along with the CCR3 reporter. After 
36 h, luciferase activity was measured and normalized to Renilla 
luciferase activity. Data represent the mean±SEM of three independent 
experiments. Statistical significance was obtained using ANOVA, 
compared with scrambled siRNA. *p<0.01.
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mutations of one of the two RUNX1 sites along with the 
GATA site produced opposing results: one with mutation 
of the distal RUNX1 site (Construct 5) had reduced 
reporter activity with an additive effect of the GATA 
mutation, whereas the other with mutation of the proximal 
RUNX1 site (Construct 6) had increased activity. These 
RUNX1 sites constitute position-dependent positive and 
negative regulatory elements in the context of the major 
transcriptional regulatory element, the GATA site, thus 
contributing to fine-control of transcription of the CCR3 
gene. Both functionally positive and negative interactions 
between RUNX1 and GATA factors have been exempli-
fied in a previous report, in which αIIb integrin promoter 
in megakaryocytes is activated or repressed by a subtle 
difference in interaction of RUNX1 and GATA-1 (21).
  The point mutant of the PU.1 sites (construct 7 in 
Fig. 3B) exhibited slightly but significantly reduced the 
reporter activity. The effect of PU.1 mutation (con-
struct 7) was comparable to or slightly less than the 
effects of the RUNX1 mutations (constructs 3 and 4). 
A double mutation (construct 8) in the PU.1 site 
along with the GATA site yielded additively reduced 
activity. PU.1 is critical for normal granulocytic dif-
ferentiation. Disruption of the PU.1 gene affects mul-
tiple hematopoietic lineages, including defects in granu-
locyte terminal differentiation, resulting in the loss of 
functionally mature neutrophils and eosinophils (11,12, 
22). Furthermore, PU.1 activates transcription of the 
MBP  gene, a representative eosinophil-specific gene. 
The MBP reporter is transactivated at a modest level by 
PU.1 alone but is synergistically transactivated by PU.1 
and GATA-1. Removal of the PU.1 sites in the MBP 
promoter results in a modest decrease in reporter activity, 
while GATA mutations greatly reduced reporter activity 
(23). Our results are largely consistent with PU.1 and 
GATA-1 regulation of the MBP promoter. PU.1 siRNA 
and elimination of PU.1 sites modestly reduced the 
CCR3 reporter. A combined effect of PU.1 and GATA-1 
Figure 3. Effects of point mutants of RUNX1 and 
PU.1 binding motifs on CCR3 reporter activity. 
(A) Nucleotide sequence of the regulatory region 
construct 1 containing exon 1 and proximal intron 
1 of the CCR3 gene. The sites for RUNX1 and 
PU.1 are underlined, as is the functional GATA 
site. (B) Point mutants were constructed and 
transfected into EoL-1 and Jurkat cells. Reporter 
activity was measured 48 h post-transfection. 
Transfection efficiency was normalized to 
cotransfected Renilla luciferase activity. Open 
and filled symbols indicate wild-type and mutant 
sites, respectively. Data represent the mean±SEM 
of three independent experiments performed in 
triplicate. *p<0.01.
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was observed, although the effect was not synergistic, as 
evidenced by additive decreases upon elimination of both 
PU.1 and GATA sites (construct 8 in Fig. 3B) and the 
inclusion of PU.1 and GATA-1 siRNAs. PU.1 is definitely 
involved in CCR3 transactivation. 
  We next examined in vitro  binding of RUNX1 and 
PU.1 to their putative elements. When nuclear extract 
from EoL-1 and Jurkat cells was reacted with each probe 
of the two RUNX1 sites, two DNA-protein complexes 
were formed. Incubation with anti-RUNX1 antibody 
induced formation of a supershifted band only with the 
fast-migrating species. The supershifted band overlapped 
with the slow migrating band that remained unchanged 
even in the presence of the anti-RUNX1 antibody. In 
contrast, the control antibody had no effect (Fig. 4). 
The DNA-protein complex was formed to a greater 
extent with the distal RUNX1 probe than that with the 
proximal RUNX1 probe. This result was opposite to 
that of reporter assays, in which the effect of the distal 
RUNX1 mutation was smaller than that of the proximal 
RUNX1 mutation. This discrepancy might be due to 
the fact that the EMSA probes used only include the 
RUNX1 sites themselves, while the reporter activities are 
resulted from the sequences containing both RUNX1 and 
GATA sites. Thus, these data indicate that the capacity of 
transactivation of functional elements is not necessarily 
consistent with their in vitro binding capacity. In addition, 
the in vitro binding capacity does not, as most likely that 
often reflect. A similar result was observed with nuclear 
extract from Jurkat cells with a slightly different pattern 
of formed DNA-protein complex, which was specific as 
judged by the supershifted band (Fig. 4). In contrast to 
RUNX1 binding, a DNA-protein complex was observed 
but not supershifted by the two anti-PU.1 antibodies used 
(Fig. 4).
  In summary, we for the first time demonstrate the invol-
vement of RUNX1 and PU.1 in transcriptional control 
of an eosinophil-specific gene. Thus, RUNX1 and PU.1 
might regulate the CCR3 gene by binding their cis-acting 
elements in its regulatory region in conjunction with 
GATA-1.
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